BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 31063269)

  • 21. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Plasma MIF and VCA-IgA Improves the Diagnostic Specificity for Patients With Nasopharyngeal Carcinoma.
    Xue N; Xing S; Ma W; Sheng J; Huang Z; Xu Q
    Technol Cancer Res Treat; 2020; 19():1533033820935773. PubMed ID: 32578505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
    Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
    J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wild-type IDH2 contributes to Epstein-Barr virus-dependent metabolic alterations and tumorigenesis.
    Shi F; He Y; Li J; Tang M; Li Y; Xie L; Zhao L; Hu J; Luo X; Zhou M; Liu N; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Jia W; Bode AM; Cao Y
    Mol Metab; 2020 Jun; 36():100966. PubMed ID: 32224436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
    Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
    Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
    Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
    Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana.
    Ayee R; Ofori MEO; Tagoe EA; Languon S; Searyoh K; Armooh L; Bilson-Amoah E; Baidoo K; Kitcher E; Wright E; Quaye O
    Viruses; 2020 Jul; 12(7):. PubMed ID: 32708700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres.
    Chen Y; Xu Y; Zhao W; Xiao X; Zhou X; Lin L; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    BMC Cancer; 2018 Feb; 18(1):190. PubMed ID: 29444646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Glypican-4 Gene Polymorphism rs1048369 and Susceptibility to Epstein-Barr Virus-Positive and -Negative Nasopharyngeal Carcinoma in Northern China.
    Liu S; Liu W; Zhao D; Zhang Y; Zhao Z; Luo B
    Oncol Res Treat; 2019; 42(11):572-579. PubMed ID: 31522169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
    Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
    BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study.
    Du JL; Chen SH; Huang QH; Xie SH; Ye YF; Gao R; Guo J; Yang MJ; Liu Q; Hong MH; Cao SM
    Chin J Cancer; 2016 Aug; 35(1):78. PubMed ID: 27527073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Epstein-Barr virus antibodies EA-IgG, Rta-IgG, and VCA-IgA in nasopharyngeal carcinoma and their use in a combined diagnostic assay.
    Li Y; Wang K; Yin SK; Zheng HL; Min DL
    Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27050964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma.
    Deng Y; Liu X; Huang Y; Ye J; He Q; Luo Y; Chen Y; Li Q; Lin Y; Liang R; Li Y; Wei J; Zhang J
    Cell Oncol (Dordr); 2023 Aug; 46(4):987-1000. PubMed ID: 36917356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
    Yu KJ; Hsu WL; Pfeiffer RM; Chiang CJ; Wang CP; Lou PJ; Cheng YJ; Gravitt P; Diehl SR; Goldstein AM; Chen CJ; Hildesheim A
    Clin Cancer Res; 2011 Apr; 17(7):1906-14. PubMed ID: 21447725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral Microbiota Alteration and Roles in Epstein-Barr Virus Reactivation in Nasopharyngeal Carcinoma.
    Liao Y; Zhang JB; Lu LX; Jia YJ; Zheng MQ; Debelius JW; He YQ; Wang TM; Deng CM; Tong XT; Xue WQ; Cao LJ; Wu ZY; Yang DW; Zheng XH; Li XZ; Wu YX; Feng L; Ye W; Mu J; Jia WH
    Microbiol Spectr; 2023 Feb; 11(1):e0344822. PubMed ID: 36645283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
    Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
    Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.